ReviewFrontiers in surgery2023
Characteristics and treatment strategies of aggressive angiomyxoma in women: A retrospective review of 87 cases.
Review in Frontiers in surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Preoperative Arterial Embolization Facilitating Safe Resection of a Hypervascular Aggressive Angiomyxoma: A Case Report.Clinical case reports · 2026Article
- Case Report: Pelvic-perineal deep angiomyxoma presenting as hematoma-like paravaginal masses: a report of two cases.Frontiers in oncology · 2026Article
- Case Report of an Aggressive Angiomyxoma Presenting as Pelvic Organ Prolapse.Case reports in obstetrics and gynecology · 2026Article
- Vulvar Aggressive Angiomyxoma in a Postmenopausal Woman: Diagnostic Pitfalls and Surgical Implications-A Case Report.Case reports in obstetrics and gynecology · 2026Article
- A Case for the Use of Combined Hormonal Therapy for Aggressive Angiomyxoma: Complete Response to Goserelin and Letrozole Following Incomplete Surgical Resection.Clinical case reports · 2025Article
- Recurrent Aggressive Angiomyxoma That Responded to the Gonadotropin-Releasing Hormone (GnRH) Antagonist Relugolix.Cureus · 2025Article
- Review
- Imaging features of a rare giant intra-abdominal aggressive angiomyxoma.Radiology case reports · 2024Article
- Atypical Vaginal Aggressive Angiomyxoma in a Virgin: A Case Report from South Jordan.International journal of women's health · 2024Article
- Second recurrence of aggressive vulvar angiomyxoma: a case report.The Journal of international medical research · 2023Article
- Superficial Angiomyxoma Revisited.In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Aggressive angiomyxoma (AAM) is a rare kind of soft tissue tumor. The purpose of this study is to summarize the clinical manifestations and treatment strategy of AAM in women. Method: We searched the case reports on AAM in EMBASE, Web of Science and PubMed, China biomedical database, Wanfang database, VIP database, and China National Knowledge Internet from the start of database construction to November 2022 without any language restrictions in place. Then, the obtained case data were extracted, summarized, and analyzed. Result: A total of 74 articles were retrieved involving 87 cases. The age ranges of onset were 2-67 years. The median age at onset was 34 years. The size of the tumor varied greatly among individuals, and about 65.5% of them were asymptomatic. MRI, ultrasound, and needle biopsy were used for diagnosis. Surgery was the primary mode of treatment, but it was prone to relapse. Gonadotropin-releasing hormone agonist (GnRH-a) might be used to reduce the tumor size before the operation and prevent recurrence after the operation. For patients who are unwilling to receive surgical treatment, GnRH-a alone could be attempted. Conclusion: Doctors should consider the possibility of AAM in women with genital tumors. For surgery, it must be ensured that the negative surgical margin is recommended and achieved for preventing recurrence, but we should not ignore the impact of the excessive pursuit for a negative margin on the patient's reproductive function protection and postoperative recovery. Long-term follow-up is necessary regardless of whether patients receive medical treatment or surgical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.